Outlook Therapeutics (OTLK) plunged over 66% in premarket trade after the US FDA declined approval of its investigational drug Lytenava for wet age-related macular degeneration, citing insufficient evidence of effectiveness. Wet AMD, a severe retinal disease causing rapid vision loss, affects millions over age 50. The rejection is a major setback for the biotech firm.